{"id":"placebo-cagrilintide","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL4802169","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cagrilintide mimics amylin, a hormone co-secreted with insulin that regulates postprandial glucose levels and promotes feelings of fullness. By activating amylin receptors in the brain and gastrointestinal tract, it delays stomach emptying and enhances satiety signaling, leading to reduced caloric intake and weight loss. It is being developed as a combination therapy with GLP-1 receptor agonists for enhanced weight management efficacy.","oneSentence":"Cagrilintide is an amylin receptor agonist that slows gastric emptying and promotes satiety to reduce appetite and food intake.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:26:45.712Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities (Phase 3)"}]},"trialDetails":[{"nctId":"NCT06409130","phase":"PHASE2","title":"Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-20","conditions":"Alcohol-related Liver Disease","enrollment":270},{"nctId":"NCT05669755","phase":"PHASE3","title":"REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2023-03-01","conditions":"Cardiovascular Disease","enrollment":7101},{"nctId":"NCT07220759","phase":"PHASE3","title":"Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-11-05","conditions":"Overweight, Obesity, Type 2 Diabetes","enrollment":330},{"nctId":"NCT06403761","phase":"PHASE1","title":"Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-05-06","conditions":"Diabetes Mellitus, Type 2","enrollment":158},{"nctId":"NCT07357766","phase":"PHASE3","title":"A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-06-22","conditions":"Overweight, Obesity","enrollment":1400},{"nctId":"NCT07220642","phase":"PHASE3","title":"Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-11-05","conditions":"Obesity, Overweight","enrollment":300},{"nctId":"NCT07357740","phase":"PHASE2","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT07411560","phase":"PHASE1","title":"A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-02-09","conditions":"Overweight, Obese","enrollment":100},{"nctId":"NCT06388187","phase":"PHASE3","title":"A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-06-24","conditions":"Obesity","enrollment":300},{"nctId":"NCT07282613","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-04","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT05394519","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-01","conditions":"Overweight, Obesity, Type 2 Diabetes Mellitus","enrollment":1200},{"nctId":"NCT07253285","phase":"PHASE3","title":"A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-01-08","conditions":"Overweight, Obesity","enrollment":460},{"nctId":"NCT05813925","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-04-03","conditions":"Obesity or Overweight","enrollment":331},{"nctId":"NCT06065540","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":2734},{"nctId":"NCT06780449","phase":"PHASE3","title":"A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-02-10","conditions":"Obesity","enrollment":400},{"nctId":"NCT06323174","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-19","conditions":"Type 2 Diabetes","enrollment":189},{"nctId":"NCT05996848","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-08-15","conditions":"Obesity or Overweight","enrollment":300},{"nctId":"NCT06207877","phase":"PHASE1","title":"A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-23","conditions":"Obesity","enrollment":62},{"nctId":"NCT06267092","phase":"PHASE1","title":"A Study of How CagriSema Works on Appetite in People With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Overweight, Obesity","enrollment":164},{"nctId":"NCT04982575","phase":"PHASE2","title":"Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":92},{"nctId":"NCT07011667","phase":"PHASE3","title":"A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-03","conditions":"Obesity","enrollment":609},{"nctId":"NCT05567796","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2022-11-01","conditions":"Obesity","enrollment":3400},{"nctId":"NCT06797869","phase":"PHASE2","title":"A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-29","conditions":"Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy","enrollment":142},{"nctId":"NCT06323161","phase":"PHASE3","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-03-26","conditions":"Type 2 Diabetes","enrollment":274},{"nctId":"NCT06131372","phase":"PHASE2","title":"A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-01","conditions":"Chronic Kidney Disease, Type 2 Diabetes, Obesity","enrollment":626},{"nctId":"NCT07010432","phase":"PHASE1","title":"The Role of the Amylin Analogue Cagrilintide in Bone Metabolism","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-06-12","conditions":"Obesity","enrollment":144},{"nctId":"NCT06719011","phase":"PHASE1","title":"A Study on How NNC0174-1213 Works in People With Overweight or Obesity.","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-03","conditions":"Obesity, Overweight","enrollment":177},{"nctId":"NCT05804162","phase":"PHASE1","title":"A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-04-12","conditions":"Obesity","enrollment":107}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cagrilintide A","NNC0174-0833 A"],"phase":"phase_3","status":"active","brandName":"Placebo cagrilintide","genericName":"Placebo cagrilintide","companyName":"Novo Nordisk A/S","companyId":"novo-nordisk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cagrilintide is a protein-based medication being studied for its potential effects on conditions such as type 2 diabetes, diabetic peripheral neuropathy, obesity, and overweight. It is being investigated in combination with semaglutide, and its exact mechanism of action is not specified in the available information.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}